A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

NCT00781911 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma
Neuroendocrine Tumors

Interventions

BIOLOGICAL: Cixutumumab
DRUG: depot octreotide

Sponsor

Eli Lilly and Company